Response by Zelniker et al to Letter Regarding Article, “Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial”
Thomas A. Zelniker, Itamar Raz, Marc S. Sabatine, Stephen D. Wiviott
Topics & Concepts
MedicineDapagliflozinTIMIInternal medicineAtrial fibrillationMyocardial infarctionDiabetes mellitusCardiologyThrombolysisType 2 Diabetes MellitusEndocrinologyDiabetes Treatment and ManagementCardiovascular Function and Risk FactorsParkinson's Disease Mechanisms and Treatments